Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
OBJECTIVES: The anti-α4β7 integrin antibody vedolizumab (VDZ) is successfully used for the treatment of inflammatory bowel diseases. However, only a subgroup of patients respond to therapy. VDZ is administered at a fixed dose, leading to a wide range of serum concentrations in patients. Previous wor...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NLM (Medline)
2022
|
| Online Access: | View Fulltext in Publisher |